NASDAQ$TXMD
TherapeuticsMD Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
TherapeuticsMD transitioned to a virtual business model and reported full year 2022 financial results.
TherapeuticsMD reported full year 2022 financial results, highlighting a transition to a virtual business model following a transaction with Mayne Pharma. The company repaid its debt, redeemed preferred stock, and eliminated its commercial and manufacturing infrastructure.
- TherapeuticsMD granted Mayne Pharma an exclusive license to commercialize its products in the United States.
- The company repaid its debt and redeemed outstanding preferred stock.
- TherapeuticsMD eliminated its commercial and manufacturing infrastructure and downsized operations.
- The company intends to explore strategic pathways to create value for shareholders.
Headline financials
Revenue & EPS history
TherapeuticsMD · Revenue · Quarterly
$1.15M
Forward guidance
TherapeuticsMD is eligible to receive up to $30.0 million in milestone payments as well as royalties on net sales of between 7.5% and 8.0%, for a period of 20 years, with minimum annual royalties of $3.0 million per year for 12 years, adjusted for inflation at an annual rate of 3%, subject to certain further adjustments.
Tailwinds
- Eligible to receive up to $30.0 million in milestone payments
- Royalties on net sales of between 7.5% and 8.0% for 20 years
- Minimum annual royalties of $3.0 million per year for 12 years
- Royalties adjusted for inflation at an annual rate of 3%
- Upfront cash payment of $140.0 million for the license grant and sale of certain assets, plus an additional approximately $13.1 million for the acquisition of net working capital and prepaid royalties
Headwinds
- Milestone payments are not guaranteed
- Royalty payments are subject to sales performance
- Minimum annual royalties are subject to certain further adjustments
- Prepaid royalties paid at closing will reduce the first four quarterly royalty payments
- Winding down operations and the costs associated therewith
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.4%
Avg return
Earnings day
-1.0%
Avg return
5 days after
+0.9%
Avg return
30 days after
38%
24 / 64 earnings
Positive
+200.0%
Q1 2011
Best reaction
-27.5%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | -3.6% | -8.3% | +4.2% | |
| Q2 2025 | -0.9% | -2.7% | -1.8% | |
| Q1 2025 | -3.9% | -2.6% | -23.0% | |
| Q4 2024 | +6.1% | +20.9% | +26.1% | |
| Q3 2024 | -1.3% | -7.9% | -17.8% | |
| Q2 2024 | -1.2% | -4.0% | +2.9% | |
| Q1 2024 | +2.5% | +6.7% | -4.8% | |
| Q1 2026 | -1.9% | +6.7% | -4.8% | |
| Q4 2023 | +1.3% | -2.6% | -18.8% | |
| Q3 2023 | +17.1% | +12.4% | +18.3% | |
| Q2 2023 | -3.0% | -5.3% | -10.9% | |
| Q1 2023 | +0.2% | -1.6% | -13.9% | |
| Q4 2022 | +0.6% | +2.0% | +7.6% | |
| Q3 2022 | -15.0% | -27.8% | +0.3% | |
| Q2 2022 | +4.1% | +8.5% | -7.2% | |
| Q1 2022 | -12.1% | +1.0% | +223.1% | |
| Q4 2021 | -27.5% | -17.5% | -17.5% | |
| Q3 2021 | -12.5% | -18.1% | -37.5% | |
| Q2 2021 | -4.1% | -3.1% | -18.4% | |
| Q1 2021 | -14.8% | -18.7% | -5.5% | |
| Q4 2020 | +0.7% | -5.5% | -4.1% | |
| Q3 2020 | +10.7% | +0.8% | -4.9% | |
| Q2 2020 | -18.5% | -24.4% | -31.2% | |
| Q1 2020 | -5.8% | -5.8% | -15.1% | |
| Q4 2019 | -14.2% | -22.9% | -57.9% | |
| Q3 2019 | +4.1% | +5.2% | -10.3% | |
| Q2 2019 | +17.7% | +61.5% | +44.3% | |
| Q1 2019 | -12.8% | -20.9% | -26.8% | |
| Q4 2018 | -1.1% | +4.4% | -4.9% | |
| Q3 2018 | +6.0% | +0.4% | -3.4% | |
| Q2 2018 | -14.1% | -14.1% | +3.6% | |
| Q1 2018 | +2.2% | +4.9% | -0.7% | |
| Q4 2017 | -8.4% | -3.8% | -10.2% | |
| Q3 2017 | +27.8% | +30.0% | +33.0% | |
| Q2 2017 | -6.6% | -4.1% | +6.8% | |
| Q1 2017 | -6.4% | -6.8% | -12.2% | |
| Q4 2016 | +3.0% | +10.8% | +19.4% | |
| Q3 2016 | +0.0% | +10.5% | +19.7% | |
| Q2 2016 | +0.8% | +2.1% | -9.2% | |
| Q1 2016 | -5.8% | — | — | |
| Q4 2015 | +2.2% | — | — | |
| Q3 2015 | +2.2% | — | — | |
| Q2 2015 | -9.2% | — | — | |
| Q1 2015 | -11.6% | — | — | |
| Q4 2014 | +0.4% | — | — | |
| Q3 2014 | -15.3% | — | — | |
| Q2 2014 | +10.7% | — | — | |
| Q1 2014 | -9.0% | — | — | |
| Q4 2013 | +2.8% | — | — | |
| Q3 2013 | -10.0% | — | — | |
| Q2 2013 | -5.4% | — | — | |
| Q1 2013 | +0.4% | — | — | |
| Q4 2012 | -1.8% | — | — | |
| Q3 2012 | -8.7% | — | — | |
| Q2 2012 | +1.5% | — | — | |
| Q1 2012 | -2.0% | — | — | |
| Q4 2011 | -3.6% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +200.0% | — | — | |
| Q4 2010 | -25.0% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro